Cilta-Cel Yields Long-Term Efficacy in Pretreated R/R Multiple Myeloma
A single infusion of ciltacabtagene autoleucel produces a manageable safety profile among patients with relapsed/refractory multiple myeloma in the phase 1b/2 CARTITUDE-1 study.
Acalabrutinib Combo Shows Promising Outcomes in Mantle Cell Lymphoma
Overall survival rates at 12 and 36 months appear to favor the addition of acalabrutinib to bendamustine and rituximab in the treatment of those with mantle cell lymphoma in a phase 1b trial.
BET Inhibitor Combo Yields Robust Spleen Volume Reduction, Acceptable Safety
Most treatment-related adverse effects were low-grade following treatment with BMS-986158 plus ruxolitinib or fedratinib in a population of patients with intermediate- or high-risk myelofibrosis.
Polatuzumab Vedotin Plus R-mini-CHOP Does not Increase High-Grade AEs in DLBCL
Replacing vincristine with polatuzumab vedotin in R-mini-CHOP, although it hasn’t increased grade 3/4 hematologic toxicity, may increase gastrointestinal adverse effects in a cohort of frail patients with diffuse large B-cell lymphoma.
Teclistamab Combo Yields Responses, No New Toxicity in R/R Multiple Myeloma
Findings from the phase 1b RedirecTT-1 study may support initiating larger studies evaluating teclistamab plus talquetamab for patients with relapsed or refractory multiple myeloma.
Acalabrutinib Yields No Unexpected Safety Signals in Older CLL Population
Investigators identify only 1 death related to treatment with acalabrutinib among older, frail patients with chronic lymphocytic leukemia in the phase 2 CLL-FRAIL trial.
Daratumumab Combo Yields Responses in Pretreated R/R Multiple Myeloma
Results from the phase 2 DARIA trial found an improved overall response rate in patients given daratumumab, ixazomib, and dexamethasone with relapsed/refractory multiple myeloma who were previously treated with lenalidomide.
RG6234 Shows Promise as Monotherapy in Heavily Pretreated Multiple Myeloma
Data presented at the 2022 European Hematology Association Congress demonstrated potential utility of the bispecific antibody RG6234 in a previously treated cohort of patients with multiple myeloma.
Early Findings Highlight Promising Outcomes With REGN5458 in Relapsed/Refractory Multiple Myeloma
Patients with relapsed/refractory multiple myeloma experienced promising responses with REGN5458.
Similar OS and Transplantation Observed With Decitabine vs Chemo in Geriatric AML
Older patients with acute myeloid leukemia who were treated with decitabine experienced comparable outcomes vs daunorubicin and cytarabine.
Venetoclax Plus Obinutuzumab Yield PFS Improvement in Untreated CLL, With or Without Ibrutinib
Patients with treatment-naïve chronic lymphocytic leukemia who were treated with venetoclax and obinutuzumab with or without ibrutinib experienced a progression-free survival benefit compared with standard chemoimmunotherapy.
Quizartinib Added to Chemo Boosts Overall Survival in FLT3-ITD–positive AML
The combination of quizartinib plus chemotherapy yielded better survival outcomes vs chemotherapy alone in the frontline setting of FLT3-ITD-positive acute myeloid leukemia.
Epcoritamab Yields Durable Responses in Relapsed/Refractory LBCL
An expansion cohort from the phase 2 EPCORE NHL-1 trial demonstrated strong efficacy of epcoritamab in patients with relapsed/refractory large B-cell lymphoma.
Shaji Kumar, MD, Details Toxicities With Daratumumab Plus Lenalidomide/Dexamethasone in Frontline MM
At EHA 2021, Shaji Kumar, MD, reviews the toxicity profile of daratumumab plus lenalidomide and dexamethasone for patients with transplant-ineligible multiple myeloma in the first-line setting.
Shaji Kumar, MD, Reviews PFS With Daratumumab-Containing Therapy in Frontline Myeloma
At EHA 2021, Shaji Kumar, MD, reflects on the significance of 5-year data from the MAIA study of a daratumumab combination in patients with multiple myeloma.
Shaji Kumar, MD, Discusses 5-Year Overall Survival Data for MM Daratumumab Combo in the MAIA Study
At EHA 2021, Shaji Kumar, MD, reflects on the significance of 5-year data from the MAIA study of daratumumab plus lenalidomide/dexamethasone in patients with newly diagnosed multiple myeloma.
Shaji Kumar, MD on the Impact of Daratumumab, Lenalidomide, and Dexamethasone in Transplant-Ineligible Newly Diagnosed MM
Shaji Kumar, MD, talks about 5-year follow-up data regarding the use of daratumumab, lenalidomide, and dexamethasone in patients with multiple myeloma who are not eligible for transplant.
Improved OS Seen With Momelotinib-Associated Transfusion Independence at 24 Weeks in Myelofibrosis
Data presented from the phase 3 SIMPLIFY 1 and SIMPLIFY 2 trials at 2021 EHA indicate success of momelotinib in extending overall survival in patients with myelofibrosis who achieve transfusion independence.
Longer Follow-Up Shows Cilta-Cel Induces Deep, Durable Responses in Relapsed/Refractory MM
At the 18-month follow-up, the CAR T-cell therapy led to early, deep, and durable responses with a manageable safety profile in patients with relapsed/refractory multiple myeloma.
Saad Z. Usmani, MD, MBA, FACP, Talks About Durable and Deep Responses of Cilta-Cel for Patients With Multiple Myeloma
Usmani noted the strong overall response and stringent complete response rates observed with ciltacabtagene autoleucel for multiple myeloma at a median follow-up of 18 months.
Data Collected in Patients With DLBCL Reveal Real-World Trends for Use of Axi-Cel and Tisa-Cel
Real-world data regarding the use of tisagenlecleucel and axicabtagene ciloleucel CAR T-cell therapy are reported at 2021 EHA.
Daratumumab Plus CyBorD Followed by Daratumumab Maintenance Achieves Deep Responses for Multiple Myeloma
An end-of-study analysis of the LYRA trial found that patients with treatment-naïve and relapsed multiple myeloma achieved durable responses to daratumumab plus CyBorD induction followed by daratumumab maintenance therapy.
Maintenance With Rituximab for MCL Prolongs Time to Next Treatment
Real-world evidence evaluating the efficacy of rituximab maintenance following frontline BR or R-CHOP supports its use in mantle cell lymphoma.
Intervention Analysis for Cilta-Cel–Associated Neurotoxicity in R/R Myeloma Presented at 2021 EHA
Close monitoring for neurologic toxicity resulted in no long-term effects in a patient cohort treated with ciltacabtagene autoleucel for relapsed/refractory multiple myeloma.
Patients With MPNs May Require More Cardiovascular Risk Management
Retrospective data presented at 2021 EHA revealed potential treatment gaps in the management of patients with myeloproliferative neoplasms.
Three-Year Follow-Up Continues to Support Fixed-Dose Venetoclax/Obinutuzumab in Treatment-Naïve CLL
A progression-free survival advantage persisted at the 3-year mark with venetoclax plus obinutuzumab in patients with previously untreated chronic lymphocytic leukemia.
Relapsed/Refractory Follicular Lymphoma Experiences Better Outcomes With Axi-Cel Vs Currently Available Therapies
Treatment with axicabtagene ciloleucel resulted in improved survival and tumor responses in patients with relapsed/refractory follicular lymphoma versus other available therapies.
Relapsed/Refractory DLBCL Has Extended Response Duration With Naratuximab Emtansine Plus Rituximab
Clinical activity with the combination of naratuximab emtansine plus rituximab was observed in patients with relapsed or refractory diffuse large B-cell lymphoma.
Combination Therapy With Ibrutinib and Venetoclax Bests Chlorambucil/Obinutuzumab for CLL
The risk of progression or death was statistically significantly reduced with the use of ibrutinib and venetoclax versus chlorambucil plus obinutuzumab in patients with treatment-naive chronic lymphocytic leukemia.
Addition of Daratumumab to SOC Continues to Improve Survival in Newly Diagnosed MM
After almost 5 years of follow-up, results strongly support upfront daratumumab with lenalidomide and dexamethasone as a new standard of care for patients with transplant-ineligible newly diagnosed multiple myeloma.
2 Clarke Drive Cranbury, NJ 08512